Colorectal cancer screening just got a new option — but physicians are concerned that the most important fact about this new test is getting lost in the enthusiasm for a less invasive alternative to colonoscopy.
In May 2026, the American Cancer Society updated its colorectal cancer screening guidelines to include the Shield blood test, developed by Guardant Health, as a qualifying screening option for average-risk adults. The Shield test requires only a blood draw and no bowel preparation — making it substantially more accessible for patients who have declined or delayed colonoscopy for years.
The problem, according to physicians and the ACS itself, is that the Shield test is not equivalent to colonoscopy. It is not designed to be, and using it as a colonoscopy substitute — which is already happening — carries real clinical risk.
Colorectal cancer is now the leading cause of cancer death in Americans under 50. Most of those deaths are preventable if the disease is caught early, or if the polyps that become cancer are found and removed before cancer develops.
Why This Matters
The distinction between finding cancer and finding precancerous polyps is central to why this story matters.
A colonoscopy does two things: it looks for existing cancer, and it finds and removes precancerous polyps before they have a chance to become cancer. The removal of adenomatous polyps during colonoscopy is one of the primary reasons colorectal cancer mortality has declined over the past 30 years.
The Shield test looks for circulating tumor DNA — genetic fragments shed by cancer cells into the bloodstream. It is relatively good at detecting cancer that already exists. It is significantly less effective at detecting early-stage cancer. And it is nearly unable to detect precancerous polyps, because polyps shed minimal tumor DNA into the blood before becoming invasive.
If patients choose the Shield blood test as their only colorectal cancer screening tool, the test may reassure them that no cancer is present — while leaving undetected polyps to develop into cancer over the following years. That is precisely the scenario the ACS and gastroenterologists are working to prevent.
What We Know So Far
The Shield test's clinical data show that it detects 83% of existing colorectal cancers when tested across a clinical trial population — a meaningful detection rate, but lower than colonoscopy, which is considered the gold standard with the highest sensitivity for both cancer and polyps.
More critically:
- Shield's sensitivity for early-stage (Stage I and II) colorectal cancer is significantly lower than its overall cancer detection rate
- Shield has limited sensitivity for advanced precancerous adenomas, which are the primary targets of colonoscopy-based prevention
- Shield has a specificity of approximately 90%, meaning approximately 10% of positive Shield results are false positives in people without cancer — which would trigger a diagnostic colonoscopy anyway
The ACS's updated guidelines are clear on appropriate use: the Shield test is recommended only for patients who cannot or will not undergo colonoscopy, a stool-based test (FIT or Cologuard), or another recommended screening method. It is explicitly not positioned as an equal alternative to colonoscopy. Patients who screen positive on Shield still require a colonoscopy for diagnosis.
Where the Risk Is Highest
The risk of inappropriate substitution is highest in several specific patient populations:
- Patients who have repeatedly declined or deferred colonoscopy and who may embrace the blood test as a permanent alternative
- Primary care clinicians who offer the Shield test without clearly explaining its limitations relative to colonoscopy
- Patients in geographic areas with high rates of unscreened individuals, where any screening option may be presented as better than none — without the caveat that it is not equivalent
Colorectal cancer rates are rising specifically in younger adults under 50 — the age group least likely to have had a colonoscopy and most likely to be newly offered a blood test option. In this demographic, detecting polyps early is especially critical, and the Shield test's limited polyp detection sensitivity is most consequential.
What Doctors and Experts Say
Gastroenterologists and oncologists responding to the ACS guideline update have consistently emphasized that the Shield test is a tool to increase overall screening participation — not to replace the most effective prevention strategy.
The core clinical message is this: if you can get a colonoscopy, you should get a colonoscopy. The Shield test exists for people who won't or can't — not as a simpler version of the same thing.
The ACS's own guideline language reflects this: the Society recommends the blood-based test specifically for patients who are unwilling to undergo other forms of screening. That framing — "unwilling" rather than "choosing between equivalent options" — is intentional.
Physicians also note that a negative Shield result, while reassuring for a cancer that is already present, does not mean the colon is polyp-free. Patients who receive a negative Shield result may incorrectly believe their colon health has been fully assessed.
What the Evidence Shows — and What It Does Not
The Shield test's clinical evidence is based on the ECLIPSE trial, a prospective study that compared the test against colonoscopy findings in a large screening population. The trial's findings informed the FDA's approval of Shield for adults 45 and older at average risk.
MedicalDaily Evidence Check
- Test name : Shield (Guardant Health); also known as ctDNA blood-based colorectal cancer screening test
- FDA approval status : Approved for average-risk colorectal cancer screening in adults 45+
- ACS guideline addition : May 2026 (as an option for patients unwilling or unable to undergo colonoscopy or stool-based tests)
- Sensitivity for existing colorectal cancer : ~83%
- Sensitivity for early-stage cancer : Significantly lower than overall cancer sensitivity
- Sensitivity for precancerous polyps (adenomas) : Substantially limited; not designed as a polyp detection tool
- Specificity : ~90% (approximately 10% false positive rate)
- Key limitation : Does not detect the polyps that colonoscopy is designed to find and remove; positive results still require colonoscopy
- What readers should know : The Shield test is an option for patients who decline other screening — not an equivalent replacement for colonoscopy or stool-based tests
Who Faces the Greatest Risk?
Patients at heightened risk of harm from using Shield as a colonoscopy substitute include:
- Anyone under 45 who believes a blood test substitutes for a colonoscopy (Shield is approved for 45+ only)
- Individuals with a family history of colorectal cancer or a personal history of polyps, who are typically directed to earlier and more frequent colonoscopy regardless of other test options
- People who receive a negative Shield result and then postpone or cancel a scheduled colonoscopy
- Patients at higher-than-average risk due to inflammatory bowel disease, Lynch syndrome, or other hereditary colorectal cancer syndromes — for whom standard blood-based screening is not recommended
Symptoms and Warning Signs to Watch For
Colorectal cancer in its early stages often produces no symptoms. When symptoms do appear, they may include:
- Changes in bowel habits lasting more than a few days (diarrhea, constipation, or narrowing of stool)
- Rectal bleeding or blood in the stool
- Persistent cramping or abdominal discomfort
- A feeling that the bowel does not empty completely
- Unexplained weight loss
- Persistent fatigue or weakness not otherwise explained
Anyone with these symptoms — regardless of age or most recent screening result — should contact a gastroenterologist or primary care provider promptly. A blood-based test is not designed to evaluate symptomatic colorectal concerns; direct colonoscopy is the appropriate next step.
What You Can Do Now
- If you have never been screened for colorectal cancer , start the conversation with your doctor about which option is right for you — and understand the differences before choosing. The ACS recommends screening beginning at age 45 for average-risk adults.
- If you are offered the Shield test as an option , ask your doctor specifically about the test's limitations in detecting polyps — and whether you might be a candidate for colonoscopy or a stool-based test instead.
- If you receive a negative Shield result , discuss with your provider what follow-up is recommended and when your next screening should occur. A negative blood test does not mean the next colonoscopy can be indefinitely postponed.
- If a Shield test is positive , a colonoscopy will be required for diagnosis — contact your provider to arrange this as soon as possible.
- Do not use the availability of a blood test as a reason to delay addressing colorectal cancer symptoms. Blood-based screening is for asymptomatic, average-risk adults only.
Cost and Access: What Patients Should Know
The Shield test costs approximately $895 without insurance. Medicare coverage for Shield is available under certain conditions, and private insurance coverage varies widely by plan. Before ordering the test, patients should verify their specific plan's coverage and any applicable cost-sharing.
By comparison, colonoscopy is covered at no cost to the patient under the ACA's preventive services provisions for most private insurance plans, and under Medicare at no cost for screening colonoscopies in patients who meet age and risk criteria.
Stool-based tests (FIT or multi-target stool DNA/Cologuard) are also widely covered and cost substantially less than the Shield blood test — and they are more effective at detecting precancerous polyps than Shield.
For patients without insurance, federally qualified health centers and many state cancer screening programs offer colonoscopy access at reduced or no cost. The CDC's Colorectal Cancer Control Program provides funding for screening in underserved populations across multiple states.
What Happens Next
The ACS's updated guidelines are a living document, and the Society has indicated it will continue to review new evidence as clinical experience with Shield accumulates. The FDA may also receive additional data from Guardant Health regarding Shield's performance in real-world screening populations, which could inform future label updates or clinical guidelines.
Gastroenterologists and primary care providers are being encouraged to develop clear patient communication materials that accurately describe what Shield does — and does not — do to prevent widespread use of the test as a colonoscopy substitute.
MedicalDaily will report on any new clinical data, guideline changes, or insurance coverage developments related to blood-based colorectal cancer screening.
The Bottom Line
The Shield blood test is a legitimate, FDA-approved colorectal cancer screening option for patients who cannot or will not undergo colonoscopy — and adding any option that increases screening participation is worthwhile. But it is not equivalent to colonoscopy. It cannot replace the procedure that finds and removes the polyps that cause cancer in the first place. If you have been offered the Shield test as a replacement for colonoscopy, ask your doctor to explain the difference. If a colonoscopy is feasible for you, the evidence still supports it as the most complete protection available.
